Welcome to our dedicated page for Seelos Therapeutics news (Ticker: SEEL), a resource for investors and traders seeking the latest updates and insights on Seelos Therapeutics stock.
Seelos Therapeutics, Inc. (SEEL) is a clinical-stage biopharmaceutical company advancing novel therapies for central nervous system disorders and rare diseases. This page provides a comprehensive repository of official news releases and curated updates on the company’s clinical progress, regulatory milestones, and strategic initiatives.
Investors and industry stakeholders will find timely updates on Seelos’ pipeline developments, including SLS-002 for acute suicidal ideation, SLS-005 targeting protein stabilization in Sanfilippo syndrome, and SLS-006 for Parkinson’s disease. The collection spans clinical trial results, FDA communications, research collaborations, and financial disclosures essential for informed decision-making.
Content is organized to prioritize material events while maintaining accessibility for both professional analysts and general audiences. Regular updates ensure stakeholders stay informed about Seelos’ progress in addressing unmet medical needs through innovative drug delivery systems and targeted therapeutic approaches.
Bookmark this page for direct access to verified SEEL news, or subscribe to Stock Titan alerts for real-time updates on biopharmaceutical developments impacting investment and therapeutic landscapes.
Seelos Therapeutics (Nasdaq: SEEL) announced the initiation of its Expanded Access Program (EAP) for patients with Amyotrophic Lateral Sclerosis (ALS) who do not qualify for existing clinical trials. Funded by a NINDS grant under the ACT for ALS, the program aims to enroll 70 patients over 24 weeks to evaluate SLS-005. This investigational treatment is designed to stabilize proteins and activate autophagy. The CEO expressed gratitude for community support and emphasized the importance of the EAP for ALS patients lacking other therapy options. The ongoing Phase II/III study on the HEALEY ALS Platform will run concurrently.
Seelos Therapeutics (Nasdaq: SEEL) provided an update on March 29, 2023, focusing on its clinical programs. The company is temporarily pausing patient enrollment in the SLS-005-302 study for spinocerebellar ataxia type 3 (SCA3) due to financial considerations, although current participants will continue in the study. Seelos aims to concentrate resources on the SLS-002 study for Acute Suicidal Ideation and Behavior with expected data readout by Q3 2023, and the SLS-005 study for ALS data in late 2023. Seelos' corporate structure allows for strategic flexibility while extending its cash runway for upcoming data readouts.
Seelos Therapeutics, Inc. (NASDAQ: SEEL) announced a registered direct offering of 12,059,298 shares of common stock and warrants for 26,750,000 shares at a price of
Seelos Therapeutics, Inc. (NASDAQ: SEEL) announced its participation in the 43rd Annual Cowen Health Care Conference happening in Boston, Massachusetts from March 6-8, 2023. CEO Raj Mehra and senior management will host meetings during the event. Seelos is focused on developing therapies for central nervous system disorders and rare diseases, with a portfolio targeting conditions like Acute Suicidal Ideation in Major Depressive Disorder and various neurodegenerative diseases including ALS and Huntington’s disease. For more details, visit their website.
FAQ
What is the current stock price of Seelos Therapeutics (SEEL)?
What is the market cap of Seelos Therapeutics (SEEL)?
